Ainnocence’s new tech milestone grips speed in screening of infinitely small molecule and antibody candidates

Introduction

Ainnocence, a leading and smart biotech company known for its implementation of self-discovered AI tools/platforms and approaches to evolve drug discovery, has built trust among giants and existing healthcare companies for tech-based solutions. The popular platform, such as CarbonAI® refine and designs antibodies and small molecules quickly, magnifying chemical areas and so on for qualified drug candidates. The company promise speed, accuracy and innovation through its AI-specialised platform service.

Announcement

Ainnocence is stepping into the new milestone with its artificial intelligence-inspired drug discovery in the white paper through C&EN. C&EN is a robust sequence-first AI platform that can screen infinite antibody and small molecule candidates in an hour throughout the whole genome space just on one GPU, eliminating dependency on 3D structural modeling.

This thought marks a major transition to analyse the therapeutic candidates' exploration and replacement stages of computationally rich systems and structure based suimulations like AlphaFold with straight learning from experimental data and biological sequences. The results gives green signal to this approach and how it's ideal for early-stage drug discovery. Ainnocence considered an invisible binocular to assess its suitability as new tech, with science calling for precision, as patients' health is gold.

Heroic transformation

Ainnocence’s platform has beaten traditional AI drug discovery pipeline with its convictional sequence level. This new platform succeeded in mitigating wet-lab time and cost by 80%, and around 10-60% experimental rates are satisfying the industry averages. Alongside, it offers entire proteome virtual screening with no solved structures, and has won over 60 screening projects. Apart from speedy evaluation, it encompasses natural disordered motifs and proteins and targeted families.

CEO and Founder of Ainnocence, Lurong Pan, said, “Drug discovery is a crucial area where if you miss out on one constraint, then the candidate collapses. Following this concern, our sequence-based AI enable us to refine manufacturability, establishment, specificity and binding at the same time, featuring the whole genome level, which was tough previously.”

This platform earned its recognition throughout 60 above therapeutic programs involving small molecules, siRNA, synthetic biology, cell therapies and antibody applications. In one of the studies, the Company’s robust computationally engineered mutation-resistant antibodies against the SARS-CoV-2 variants evolved by illustrating model potency to study revolutionary and changing patterns easily from the sequence data. This sequence data idea eases the drug discovery process with double the awareness and knowledge to make wise choices.